Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Haemonetics (HAE) Shares Issued (2016 - 2025)

Haemonetics (HAE) has 17 years of Shares Issued data on record, last reported at $1.1 million in Q4 2025.

  • For Q4 2025, Shares Issued rose 127.13% year-over-year to $1.1 million; the TTM value through Dec 2025 reached $2.2 million, up 19.48%, while the annual FY2024 figure was $1.6 million, 38.97% down from the prior year.
  • Shares Issued reached $1.1 million in Q4 2025 per HAE's latest filing, up from $63000.0 in the prior quarter.
  • Across five years, Shares Issued topped out at $2.4 million in Q2 2021 and bottomed at $63000.0 in Q3 2025.
  • Average Shares Issued over 5 years is $650210.5, with a median of $462000.0 recorded in 2025.
  • Peak YoY movement for Shares Issued: soared 1519.7% in 2021, then crashed 86.27% in 2022.
  • A 5-year view of Shares Issued shows it stood at $1.1 million in 2021, then tumbled by 85.03% to $160000.0 in 2022, then rose by 16.25% to $186000.0 in 2023, then skyrocketed by 171.51% to $505000.0 in 2024, then soared by 127.13% to $1.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Issued were $1.1 million in Q4 2025, $63000.0 in Q3 2025, and $462000.0 in Q2 2025.